<DOC>
	<DOCNO>NCT01114048</DOCNO>
	<brief_summary>In study , investigator analyze long-term outcome remission survival , identify primary resistant disease likely benefit CTD ( thalidomide , cyclophosphamide , dexamethasone ) early intensification Vel-CD ( bortezomib CD ) induction chemotherapy follow autologous stem cell transplantation patient newly diagnose multiple myeloma .</brief_summary>
	<brief_title>Early Response-adapted Intensification Induction Chemotherapy Patients With Newly Diagnosed Multiple Myeloma ( MM )</brief_title>
	<detailed_description>This study aim assess efficacy toxicity CTD Vel-CD induction follow high-dose therapy autologous stem cell transplantation first line treatment patient multiple myeloma.The investigator already investigate thalidomide-based chemotherapy patient newly diagnose MM . The combined regimen consist cyclophosphamide , thalidomide dexamethasone ( CTD ) induction treatment . CTD chemotherapy result favorable response 79.4 % overall response rate include 42.6 % complete response ( CR ) good partial complete response ( VGPR ) , tolerable toxicity MM patient . Moreover , CTD chemotherapy affect yield stem cell collection.The investigator also publish clinical efficacy safety four-drug combination bortezomib , cyclophosphamide , thalidomide , dexamethasone assess patient relapsed refractory multiple myeloma Vel-CTD chemotherapy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Newly diagnose MM 2 . Aged 18 65 year old 3 . With follow measurable lesion ( serum Mprotein ≥ 1 g/dL urine Mprotein ≥ 400 mg/day , free light chain ≥ 100 mg/L ) 1 . Smoldering indolent myeloma 2 . ECOG performance status &gt; 3 point 3 . Known hypersensitivity cyclophosphamide , thalidomide dexamethasone 4 . Peripheral neuropathy neuropathic pain Grade 2 high define NCI CTCAE version 3 5 . Uncontrolled severe cardiovascular disease , include MI within 6 month enrolment , NYHA Class III IV heart failure , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis , cardiac ejection fraction &lt; 0.5 : Severe conduction disorder : Hypotension ( sit systolic BP ≤ 100 mmHg and/or sit diastolic BP ≤ 60 mmHg 6 . Impaired hepatic function ( AST ALT ≥ x 3 upper normal , Tbilirubin ≥ x 2 upper normal ) 7 . Creatinine clearance &lt; 20 ml/min 8 . Corrected serum calcium ≥ 14 mg/dL 9 . Sepsis current active infection 10 . Pregnancy breast feed 11 . Uncontrolled Diabetes Mellitus 12 . Previous history Recurrent DVT pulmonary embolism 13 . Active ulcer detect gastroscopy 14 . Serious medical psychiatric illness likely interfere participation clinical study . 15 . Receipt extensive radiation therapy within 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>age 65</keyword>
	<keyword>Previous untreated</keyword>
</DOC>